Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02275481 · ClinicalTrials.gov registry record · Phase 4
A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
A Phase 4 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT02275481 is a Phase 4 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 66 participants.
The verdict
NCT02275481, a Phase 4 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a randomized, open-label, parallel group, multicenter, outpatient study in COPD subjects who are discharged from the hospital due to a COPD exacerbation. Subjects who meet the eligibility criteria will be randomized to 1 of 2 treatments: arformoterol tartrate inhalation solution (BROVANA) 15 mcg twice daily (BID) or tiotropium bromide (SPIRIVA) 18 mcg once daily (QD), each given for 90 days.
Interventions
- DRUG Tiotropium
- DRUG Arformoterol tartrate inhalation solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-09-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02275481
The ClinicalTrials.gov registry entry for NCT02275481 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium is the first listed.
NCT02275481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02275481 about?
NCT02275481 is a clinical study titled "A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects". This is a randomized, open-label, parallel group, multicenter, outpatient study in COPD subjects who are discharged from the hospital due to a COPD exacerbation. Subjects who meet the eligibility criteria will be randomized to 1 of 2 treatments: arformoterol tartrate inhalation solution (BROVANA) 15...
What is the current status of trial NCT02275481?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2014-11. Estimated completion is 2016-09-14.
What interventions are being tested in trial NCT02275481?
The interventions under investigation include: Tiotropium (DRUG), Arformoterol tartrate inhalation solution (DRUG).
Who is sponsoring clinical trial NCT02275481?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.